12/15/2023 | CV | Market Commentary: Rivian convertible notes gains continue; Repligen active; Enphase strong
|
12/7/2023 | CV | Market Commentary: Nikola convertibles on tap, maybe; Repligen gains; Evergy active; Evolent down outright
|
12/7/2023 | CVLM | Repligen to swap 0.375% convertibles due 2024 for 1% convertibles due 2028
|
12/7/2023 | CV | Market Commentary: Morning Commentary: Nikola convertibles on tap; Repligen exchanges, new notes trade up
|
9/13/2022 | SP | New Issue: Citigroup prices $5 million 20.4% contingent income autocallables linked to Repligen
|
4/29/2022 | SP | New Issue: GS Finance sells $9.25 million basket-linked notes tied to 77 stocks
|
4/22/2022 | SP | New Issue: GS Finance sells $8 million basket-linked notes tied to 45 stocks
|
4/13/2022 | SP | New Issue: JPMorgan sells $145,000 capped buffered equity notes on basket of 28 biotech stocks
|
3/8/2022 | CV | Repligen amends $287.5 million 0.375% convertibles due July 2024
|
2/8/2022 | SP | New Issue: Citigroup prices $5 million contingent income autocalls on Repligen
|
1/13/2022 | SP | New Issue: JPMorgan prices $5 million contingent income autocallables on Repligen
|
11/7/2021 | SP | New Issue: UBS sells $5 million contingent income autocalls on Repligen
|
10/29/2021 | SP | New Issue: JPMorgan sells $5 million contingent income autocalls on Repligen
|
8/26/2021 | SP | New Issue: GS Finance prices $13.14 million leveraged basket-linked notes on 179 stocks
|
6/1/2021 | CV | Market Commentary: Convertibles trade quietly with upside bias in post-holiday session; Li Auto notes gain
|
6/1/2021 | SP | New Issue: JPMorgan sells $5 million contingent income autocalls on Repligen
|
6/1/2021 | CV | Market Commentary: Morning Commentary: Convertibles trading quiet early; Li Auto notes add; Pinduoduo up
|
3/19/2021 | SP | New Issue: JPMorgan sells $5 million contingent income autocalls on Repligen
|
12/5/2020 | SP | New Issue: JPMorgan sells $5 million contingent income autocalls on Repligen
|
9/4/2020 | SP | New Issue: GS Finance sells $830,000 leveraged basket-linked notes on 103 stocks
|
11/20/2019 | SP | New Issue: Barclays prices $3 million autocallable trigger jump securities on Repligen
|
10/28/2019 | SP | Barclays plans to price trigger jump autocallables linked to Repligen
|
7/22/2019 | CV | Market Commentary: Convertibles trading slow; Western Digital, Fortive notes active; Repligen improves
|
7/19/2019 | CVLM | Repligen will redeem 2.125% 2016 notes with proceeds from new notes, stock
|
7/19/2019 | CV | Repligen greenshoe exercised, lifts 0.375% convertible to $287.5 million
|
7/18/2019 | CV | Market Commentary: Senseonics prices, trades up; GOL Linhas active post add-on; Repligen holds expansion
|
7/18/2019 | CV | Market Commentary: Morning Commentary: Senseonics convertibles, GOL Linhas add-on price; Repligen quiet
|
7/17/2019 | CV | Market Commentary: Repligen prices $250 million convertibles; Gol upsizes; Suzlon defaults on $172 million
|
7/17/2019 | CV | New Issue: Repligen sells $250 million 0.375% five-year convertibles, up 32.5%
|
7/16/2019 | CV | Market Commentary: Senseonics, GOL Linhas add-on on tap; Repligen looks cheap; Twitter, Illumina active
|
7/16/2019 | CV | Market Commentary: Morning Commentary: Repligen convertible offering eyed, looks cheap; Twitter in focus
|
7/15/2019 | CV | Market Commentary: Repligen on tap; Illumina, Western Digital active; Empire State matures; Tesla rebounds
|
7/15/2019 | CV | Repligen talks $250 million five-year convertible notes to yield 0.375%-0.875%, up 27.5%-32.5%
|
4/26/2019 | BK | Repligen enters into $125 million 364-day bridge term loan
|
5/24/2016 | CV | Repligen greenshoe exercised, lifts 2.125% convertible to $115 million
|
5/19/2016 | PP | Market Commentary: Allegheny Technologies drops below par on debut; new Repligen edges up; FXCM tumbles
|
5/19/2016 | CV | Market Commentary: Allegheny Technologies drops below par on debut; new Repligen edges up; FXCM tumbles
|
5/19/2016 | CV | Market Commentary: Morning Commentary: Allegheny Technologies drops on debut; new Repligen moves up as shares weaken
|
5/19/2016 | CV | New Issue: Repligen prices $100 million five-year convertibles to yield 2.125%, up 22.5%
|
5/18/2016 | CV | Market Commentary: inContact surges on swap after takeout news; Tesla gains ahead of secondary offering news
|
5/18/2016 | CV | Repligen plans $100 million five-year convertibles to yield 1.625%-2.125%, up 22.5%-27.5%
|
11/2/2006 | BT | Repligen reports cash of $22 million, flat second-quarter revenue
|
7/31/2006 | BT | ImClone's defense of patent exhaustion eliminated in court ruling
|
7/31/2006 | BT | Market Commentary: ImClone off 4%, Repligen soars; Viragen slides, Napo debuts up; Pozen gains; Novavax up 12.5%
|
7/3/2006 | BT | Market Commentary: Encore cheered as it goes private on Blackstone buyout at a 36% premium; Siemens, Bayer up
|
6/8/2006 | BT | Repligen tests secretin for MRI imaging of the pancreas
|
3/9/2006 | BT | Repligen starts phase 2 clinical trial of RG2417 for bipolar depression
|
1/6/2006 | BT | Repligen files patent infringement suit against Bristol-Myers Squibb for Orencia
|